Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalubuminuric patients with type II diabetes

被引:22
|
作者
Shigihara, T
Sato, A
Hayashi, K
Saruta, T
机构
[1] Mito Red Cross Hosp, Dept Internal Med, Mito, Ibaraki 3100011, Japan
[2] Keio Univ, Dept Internal Med, Tokyo, Japan
关键词
type II diabetes mellitus; essential hypertension; angiotensin-converting enzyme inhibitor; calcium channel blocker; microalbuminuria;
D O I
10.1291/hypres.23.219
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
It has been demonstrated that antihypertensive treatment of hypertensive diabetic patients is quite effective in preventing macrovascular and microvascular complications and improving prognosis. Nevertheless, the target blood pressure level of antihypertensive treatment in hypertensive diabetic patients with microalbuminuria (i.e., with early diabetic nephropathy) remains to be established. In this study, we evaluated the effect of intensive blood pressure control (diastolic blood pressure <80 mmHg) on urinary albumin excretion in hypertensive, type II diabetic patients with microalbuminuria. We examined the effects of a combination therapy using an angiotensin converting enzyme (ACE) inhibitor plus a long-acting calcium channel blocker (amlodipine), and compared them with the effect of an ACE inhibitor alone. Thirty hypertensive, type II diabetic patients with microalbuminuria were treated with either an ACE inhibitor alone (group I, n=17) or an ACE inhibitor plus amlodipine (group II, n=13) for 32 weeks. With treatment, blood pressures in both groups were significantly reduced, and diastolic blood pressure was lowered to a much greater extent in group II (76 +/- 2 mmHg) than in group I (83 +/- 2 mmHg, p < 0.05). Although the urinary albumin excretion rate was decreased in both groups, the decrease attained statistical significance only in group II (from 141 +/- 25 mg/day to 69+/-18 mg/day, p<0.05); the extent of reduction in microalbuminuria during antihypertensive treatment was significantly greater in group II (50+/-10%) than in group 1 (14+/-13%, p<0.05). In conclusion, this study showed that in hypertensive microalbuminuric type II diabetic patients, the combination of an ACE inhibitor plus amlodipine resulted in a more pronounced decreased in blood pressure (diastolic blood pressure <80 mmHg) and a greater reduction in urinary albumin excretion than did use of an ACE inhibitor alone. This combination strategy should thus be a more effective tool for obtaining optimal blood pressure control in patients with diabetic nephropathy.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 50 条
  • [1] Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension
    Redon, Josep
    Trenkwalder, Peter R. A.
    Barrios, Vivencio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 155 - 164
  • [2] Advantages of combination therapy of hypertension with calcium channel blocker and angiotensin-converting enzyme inhibitor in patients with impaired renal function
    Dzhaiani, N. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2014, 10 (02) : 238 - 244
  • [3] Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients
    Kim, Yong Hoon
    Her, Ae-Young
    Rha, Seung-Woon
    Choi, Byoung Geol
    Choi, Se Yeon
    Byun, Jae Kyeong
    Kang, Dong Oh
    Jang, Won Young
    Kim, Woohyeun
    Baek, Ju Yeol
    Choi, Woong Gil
    Kang, Tae Soo
    Ahn, Jihun
    Park, Sang-Ho
    Park, Sung Hun
    Hong, Ji Yeon
    Park, Ji Young
    Lee, Min-Ho
    Choi, Cheol Ung
    Park, Chang Gyu
    Seo, Hong Seog
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2020, 19 (01) : 405 - 413
  • [4] Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients
    Yong Hoon Kim
    Ae-Young Her
    Seung-Woon Rha
    Byoung Geol Choi
    Se Yeon Choi
    Jae Kyeong Byun
    Dong Oh Kang
    Won Young Jang
    Woohyeun Kim
    Ju Yeol Baek
    Woong Gil Choi
    Tae Soo Kang
    Jihun Ahn
    Sang-Ho Park
    Sung Hun Park
    Ji Yeon Hong
    Ji Young Park
    Min-Ho Lee
    Cheol Ung Choi
    Chang Gyu Park
    Hong Seog Seo
    Journal of Diabetes & Metabolic Disorders, 2020, 19 : 405 - 413
  • [5] Beneficial effect of combination therapy using an angiotensin-converting enzyme inhibitor plus verapamil on circulating resistin levels in hypertensive patients with type 2 diabetes
    Rubio-Guerra, Alberto F.
    Vargas-Robles, Hilda
    Lozano Nuevo, Jose J.
    Elizalde-Barrera, Cesar I.
    Huerta-Ramirez, Saul
    Escalante-Acosta, Bruno A.
    EXPERIMENTAL & CLINICAL CARDIOLOGY, 2012, 17 (04) : 202 - 204
  • [6] Effects of combination therapy of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker
    Idrizi, A
    Gjata, M
    Barbullushi, M
    Koroshi, A
    Tase, M
    Sadiku, E
    Hoti, K
    JOURNAL OF HYPERTENSION, 2005, 23 : S398 - S398
  • [7] Predictors of angiotensin-converting enzyme inhibitor - Induced reduction of urinary albumin excretion in nondiabetic patients
    van de Wal, Ruud M. A.
    Gansevoort, Ron T.
    van der Harst, Pim
    Boomsma, Frans
    Thijs Plokker, H. W.
    van Veldhuisen, Dirk J.
    de Jong, Paul E.
    van Gilst, Wiek H.
    Voors, Adriaan A.
    HYPERTENSION, 2006, 48 (05) : 870 - 876
  • [8] Cardiovascular Benefits of Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Black Hypertensive Patients
    Brook, Robert D.
    Kaciroti, Niko
    Jamerson, Taylor
    Jamerson, Kenneth A.
    HYPERTENSION, 2021, 78 (04) : 1150 - 1152
  • [9] Spironolactone further reduces urinary albumin excretion and plasma b-type natriuretic peptide levles in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor
    Ogawa, S
    Takeuchi, K
    Mori, T
    Nako, K
    Ito, S
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (5-6) : 477 - 479
  • [10] Possible increase in urinary angiotensin-converting enzyme 2 by olmesartan, an angiotensin II receptor blocker, in hypertensive patients
    Furuhashi, M.
    Moniwa, N.
    Ishimura, S.
    Mita, T.
    Fuseya, T.
    Watanabe, Y.
    Ohnishi, H.
    Yoshida, H.
    Saitoh, S.
    Miura, T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 66 - 66